Forbes

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Hot-mixed Roman concrete used quicklime “healing” clasts that seal cracks over time, explaining Pompeii’s long‑lasting structures and inspiring tougher, lower‑carbon concretes today.

Dr. Paul Limburg, gastroenterologist, speaks on a non-invasive testing of colorectal cancer using Cologuard.

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions of successors to Ozempic and Wegovy.

There are political and safety considerations as the FDA looks to make more drugs OTC. Also, antibiotic resistance is a huge problem where those meds are OTC.

Five practical guardrails to get accurate, private and actionable health answers from AI chatbots — what to ask, what to avoid.

CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access and exposing fragile gene‑therapy infrastructure.

The FDA’s oversight was built for devices that rarely change. Clinical AI evolves over time, raising new questions about who is responsible for ensuring its safety.

A new study from Harvard University finds that people who live closer to nuclear power plants have a higher risk of dying from cancer than those further away.

Jack Hughes lost some teeth leading USA Hockey to the gold medal against Canada at the 2026 Winter Olympics. So, what actually happens when hockey plays loose teeth?

New findings that snakes thrive without the hunger hormone ghrelin suggest future obesity drugs could safely mute hunger at its source, complementing today’s satiety‑boosting therapies.

The KFF poll found that trust in the Centers for Disease Control and Prevention among political independents has fallen from 61 percent in 2023 to 46 percent in 2026.

Will AI lead to the "de-skilling" of doctors or create a generation of "never-skilled" ones? Here's how to mitigate the risk of clinical de-skilling.

Attention has turned to progressive supranuclear palsy, a rare neurodegenerative disorder that is often mistaken for Parkinson’s disease.